The New England journal of medicine, 2020-08, Vol.383 (6), p.546-557
- Hauser, Stephen L
- Bar-Or, Amit
- Cohen, Jeffrey A
- Comi, Giancarlo
- Correale, Jorge
- Coyle, Patricia K
- Cross, Anne H
- de Seze, Jerome
- Leppert, David
- Montalban, Xavier
- Selmaj, Krzysztof
- Wiendl, Heinz
- Kerloeguen, Cecile
- Willi, Roman
- Li, Bingbing
- Kakarieka, Algirdas
- Tomic, Davorka
- Goodyear, Alexandra
- Pingili, Ratnakar
- Häring, Dieter A
- Ramanathan, Krishnan
- Merschhemke, Martin
- Kappos, Ludwig
2020
Details
- Autor(en) / Beteiligte
- Hauser, Stephen L
- Bar-Or, Amit
- Cohen, Jeffrey A
- Comi, Giancarlo
- Correale, Jorge
- Coyle, Patricia K
- Cross, Anne H
- de Seze, Jerome
- Leppert, David
- Montalban, Xavier
- Selmaj, Krzysztof
- Wiendl, Heinz
- Kerloeguen, Cecile
- Willi, Roman
- Li, Bingbing
- Kakarieka, Algirdas
- Tomic, Davorka
- Goodyear, Alexandra
- Pingili, Ratnakar
- Häring, Dieter A
- Ramanathan, Krishnan
- Merschhemke, Martin
- Kappos, Ludwig
- Titel
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- Ist Teil von
- The New England journal of medicine, 2020-08, Vol.383 (6), p.546-557
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
- Beschreibungen/Notizen
- In two identical trials involving a total of 1882 patients with multiple sclerosis, the human anti-CD20 monoclonal antibody ofatumumab was associated with a lower annualized relapse rate than the pyrimidine-synthesis inhibitor teriflunomide, as well as fewer lesions on MRI.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1917246Titel-ID: cdi_hal_primary_oai_HAL_hal_03368307v1
- Format
- –
- Schlagworte
- Adult, Antibodies, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, B-Lymphocytes, Brain, Brain - pathology, CD20 antigen, Cell activation, Clinical trials, Crotonates, Crotonates - adverse effects, Crotonates - therapeutic use, Disease Progression, Double-Blind Method, Drug therapy, Female, Gadolinium, Human health and pathology, Humans, Injections, Subcutaneous, Injections, Subcutaneous - adverse effects, Kaplan-Meier Estimate, Lesions, Leukemia, Life Sciences, Lymphocytes B, Lymphocytes T, Magnetic Resonance Imaging, Male, Monoclonal antibodies, Multiple sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Relapsing-Remitting - drug therapy, Multiple Sclerosis, Relapsing-Remitting - pathology, Neuroimaging, Ofatumumab, Patient outcomes, Patients, Statistical analysis, T-Lymphocytes, Toluidines, Toluidines - adverse effects, Toluidines - therapeutic use